APA

Mody R., Naranjo A., Van Ryn C., Yu A. L., London W. B., Shulkin B. L., Parisi M. T., Servaes S., Diccianni M. B., Sondel P. M., Bender J. G., Maris J. M., Park J. R. & Bagatell R. (20170911). Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. : The Lancet. Oncology.

Chicago

Mody Rajen, Naranjo Arlene, Van Ryn Collin, Yu Alice L, London Wendy B, Shulkin Barry L, Parisi Marguerite T, Servaes Sabah-E-Noor, Diccianni Mitchell B, Sondel Paul M, Bender Julia G, Maris John M, Park Julie R and Bagatell Rochelle. 20170911. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. : The Lancet. Oncology.

Harvard

Mody R., Naranjo A., Van Ryn C., Yu A. L., London W. B., Shulkin B. L., Parisi M. T., Servaes S., Diccianni M. B., Sondel P. M., Bender J. G., Maris J. M., Park J. R. and Bagatell R. (20170911). Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. : The Lancet. Oncology.

MLA

Mody Rajen, Naranjo Arlene, Van Ryn Collin, Yu Alice L, London Wendy B, Shulkin Barry L, Parisi Marguerite T, Servaes Sabah-E-Noor, Diccianni Mitchell B, Sondel Paul M, Bender Julia G, Maris John M, Park Julie R and Bagatell Rochelle. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. : The Lancet. Oncology. 20170911.